Gaosi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gaosi Xu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Weiping Tu
Department of Nephrology, Second Affiliated Hospital, Nanchang University NanchangPR China
5 shared publicationsChengyun Xu
4 shared publicationsDongfeng Jiang
2 shared publicationsTianlun Huang
Department of Rheumatology, Second Affiliated Hospital, Nanchang, China
2 shared publicationsHongchang Zou
Department of Nephrology, Second Affiliated Hospital, Nanchang University, P.R. China
1 shared publicationMengyuan Liu
Department of Rheumatology; Second Affiliated Hospital; Nanchang China
1 shared publication
Latest Publications
- 24 September 2013
- Published by Taylor & Francis in Renal Failure
- Vol. 36 (1) , 126-130
Hot bath for the treatment of chronic renal failure
Background: Dialysis and its complications were debated recently. There was lack of an adjuvant renal replacement method to reduce the complications of patients with chronic renal failure and dialysis itself. Materials and methods: In this article, we reviewed the role of thermal sweating in treating of the patients with chronic renal failure, and the role of traditional Chinese medicine in the therapy of chronic kidney diseases. Results: Thermal sweating can reduce interdialytic weight gain and improve the patients’ blood pressure; Chinese herbal medicine can promote the excretion of uremic toxicities and relieve the skin disorders of these patients. Conclusions: Traditional Chinese medicine-mediated hot bath could be one of the adjuvant renal replacement methods.
- 24 September 2013
- Published by Taylor & Francis in Renal Failure
- Vol. 36 (1) , 126-130
Hot bath for the treatment of chronic renal failure
Background: Dialysis and its complications were debated recently. There was lack of an adjuvant renal replacement method to reduce the complications of patients with chronic renal failure and dialysis itself. Materials and methods: In this article, we reviewed the role of thermal sweating in treating of the patients with chronic renal failure, and the role of traditional Chinese medicine in the therapy of chronic kidney diseases. Results: Thermal sweating can reduce interdialytic weight gain and improve the patients’ blood pressure; Chinese herbal medicine can promote the excretion of uremic toxicities and relieve the skin disorders of these patients. Conclusions: Traditional Chinese medicine-mediated hot bath could be one of the adjuvant renal replacement methods.
- 2 July 2013
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 17 (1) , 122-124
Felty's syndrome with hyperthyroidism: a case report and literature review
- 2 July 2013
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 17 (1) , 122-124
Felty's syndrome with hyperthyroidism: a case report and literature review
- 30 April 2011
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 22 (2) , 161-166
Hepatitis B virus-associated glomerular nephritis in East Asia: Progress and challenges
- 30 April 2011
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 22 (2) , 161-166
Hepatitis B virus-associated glomerular nephritis in East Asia: Progress and challenges
- 17 March 2011
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (6) , 1077-1078
Treatment of hepatitis B virus-associated membranous nephritis patients in Chinese: an open parallel controlled trial
- 17 March 2011
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (6) , 1077-1078
Treatment of hepatitis B virus-associated membranous nephritis patients in Chinese: an open parallel controlled trial
- 1 June 2010
- Published by Elsevier in International Immunopharmacology
- Vol. 10 (6) , 643-647
Immunological tolerance induced by galectin-1 in rat allogeneic renal transplantation
- 1 June 2010
- Published by Elsevier in International Immunopharmacology
- Vol. 10 (6) , 643-647
Immunological tolerance induced by galectin-1 in rat allogeneic renal transplantation
- Open Access
- 13 August 2009
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (2) , 587-592
Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis
Objectives. Recently, there have been increasing concerns about the emergence of mupirocin resistance and increased infections due to lowered inhibition of Staphylococcus aureus . We conducted this systemic analysis to find out whether the application of mupirocin was effective for the prevention of exit-site infection (ESI) and peritonitis in patients undergoing peritoneal dialysis (PD). Methods. Recruited studies met the following criteria: they were randomized controlled trials or historical cohort studies; subjects consisted of adults (age, ≥ 18 years) undergoing PD; mupirocin treatment was administered to the therapy group and placebo or no treatment was administered to the control group. The primary extracted data were the difference in the episodes of ESI and peritonitis S. aureus or other organisms among treatment and control groups. Results . Fourteen studies described in 13 articles and a total of 1233 patients versus 1217 controls were included in the analysis. Of the 13 articles, 6 were newly published articles that had not been analysed previously and 3 were randomized controlled trials. The application of mupirocin decreased the risk by 72% [95% confidence interval (CI): 0.60–0.81] in ESI and by 70% (95% CI 0.52–0.81) in peritonitis due to S. aureus among all patients undergoing PD. Treatment of mupirocin reduced the risks of ESI and peritonitis due to all organisms by 57% (95% CI: 0.46–0.66) and 41% (95% CI: 0.24–0.54), respectively. Based on the six newly published articles, the reduced risk rate for mupirocin therapy was found to be 80% (95% CI: 0.39–0.93, P = 0.004) in ESI and 91% (95% CI: 0.72–0.97, P < 0.0001) in peritonitis due to S. aureus ; 70% (95% CI: 0.47–0.82, P < 0.0001) in ESI and 42% (95% CI: 0.25–0.55, P < 0.0001) in peritonitis due to all organisms among mupirocin-treated and -untreated subjects. Based on the three randomized controlled trials, ESI and peritonitis due to S. aureus were found to be reduced by 73% (95% CI: 0.63–0.80, P < 0.0001) and 40% (95% CI: 0.17–0.56, P = 0.002), respectively. Interestingly, although mupirocin treatment can reduce the risk rate of ESI by 46% (95% CI: 0.35–0.55, P < 0.00001), it cannot decrease the risk rate of peritonitis due to all organisms ( P = 0.56). Conclusions. Mupirocin prophylaxis was effective on preventing ESI and peritonitis due to S. aureus and other organisms in PD patients.
- 13 August 2009
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (2) , 587-592
Open AccessMupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis
Objectives. Recently, there have been increasing concerns about the emergence of mupirocin resistance and increased infections due to lowered inhibition of Staphylococcus aureus . We conducted this systemic analysis to find out whether the application of mupirocin was effective for the prevention of exit-site infection (ESI) and peritonitis in patients undergoing peritoneal dialysis (PD). Methods. Recruited studies met the following criteria: they were randomized controlled trials or historical cohort studies; subjects consisted of adults (age, ≥ 18 years) undergoing PD; mupirocin treatment was administered to the therapy group and placebo or no treatment was administered to the control group. The primary extracted data were the difference in the episodes of ESI and peritonitis S. aureus or other organisms among treatment and control groups. Results . Fourteen studies described in 13 articles and a total of 1233 patients versus 1217 controls were included in the analysis. Of the 13 articles, 6 were newly published articles that had not been analysed previously and 3 were randomized controlled trials. The application of mupirocin decreased the risk by 72% [95% confidence interval (CI): 0.60–0.81] in ESI and by 70% (95% CI 0.52–0.81) in peritonitis due to S. aureus among all patients undergoing PD. Treatment of mupirocin reduced the risks of ESI and peritonitis due to all organisms by 57% (95% CI: 0.46–0.66) and 41% (95% CI: 0.24–0.54), respectively. Based on the six newly published articles, the reduced risk rate for mupirocin therapy was found to be 80% (95% CI: 0.39–0.93, P = 0.004) in ESI and 91% (95% CI: 0.72–0.97, P < 0.0001) in peritonitis due to S. aureus ; 70% (95% CI: 0.47–0.82, P < 0.0001) in ESI and 42% (95% CI: 0.25–0.55, P < 0.0001) in peritonitis due to all organisms among mupirocin-treated and -untreated subjects. Based on the three randomized controlled trials, ESI and peritonitis due to S. aureus were found to be reduced by 73% (95% CI: 0.63–0.80, P < 0.0001) and 40% (95% CI: 0.17–0.56, P = 0.002), respectively. Interestingly, although mupirocin treatment can reduce the risk rate of ESI by 46% (95% CI: 0.35–0.55, P < 0.00001), it cannot decrease the risk rate of peritonitis due to all organisms ( P = 0.56). Conclusions. Mupirocin prophylaxis was effective on preventing ESI and peritonitis due to S. aureus and other organisms in PD patients.
- 14 March 2009
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 111 (4) , c223-c228
Tripterygium wilfordii Hook F Treatment for Idiopathic Refractory Nephrotic Syndrome in Adults: A Meta-Analysis
Tripterygium wilfordii Hook F (TwHF) is a Chinese herbal medicine with immunosuppressive effects and an established history of use in the treatment of inflammatory and autoimmune diseases. We have carried out a meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs which assessed the effectiveness of TwHF in the treatment for idiopathic refractory nephrotic syndrome (IRNS). After reading the full text, only three RCTs or quasi-RCTs meeting our inclusion criteria were selected. Our meta-analysis indicated that TwHF has beneficial effects on the remission of IRNS. There was no significant publication bias in the meta-analysis studies. However, studies with a larger sample size and including patients with both a mild and severe histopathological change involvement separately are needed to assess the effects of TwHF in IRNS patients before exact conclusions can be drawn.
- 14 March 2009
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 111 (4) , c223-c228
Tripterygium wilfordii Hook F Treatment for Idiopathic Refractory Nephrotic Syndrome in Adults: A Meta-Analysis
Tripterygium wilfordii Hook F (TwHF) is a Chinese herbal medicine with immunosuppressive effects and an established history of use in the treatment of inflammatory and autoimmune diseases. We have carried out a meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs which assessed the effectiveness of TwHF in the treatment for idiopathic refractory nephrotic syndrome (IRNS). After reading the full text, only three RCTs or quasi-RCTs meeting our inclusion criteria were selected. Our meta-analysis indicated that TwHF has beneficial effects on the remission of IRNS. There was no significant publication bias in the meta-analysis studies. However, studies with a larger sample size and including patients with both a mild and severe histopathological change involvement separately are needed to assess the effects of TwHF in IRNS patients before exact conclusions can be drawn.
- 31 October 2008
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 29 (5) , 362-367
Mycophenolate Mofetil Treatment for IgA Nephropathy: A Meta-Analysis
Background: Worldwide, IgA nephropathy (IgAN) is the most common type of glomerulonephritis. Mycophenolate mofetil (MMF) is relatively selective for lymphocytes and inhibits antibody production by B cells more than other immunosuppressants. Several randomized controlled trials (RCTs) have analyzed the role of MMF in patients with IgAN. We conducted this meta-analysis of all available RCTs to ascertain the benefits and risks of MMF treatment in comparison with placebos or steroids in patients with IgAN. Methods: The studies were identified by extended computer- based searches of the PubMed database (April, 2008) and the Cochrane Library, without language restriction. References in Medline-cited studies were reviewed to identify additional reports not indexed by Medline. RCTs comparing treatment of IgAN with mycophenolate against placebo or steroids were included in the analysis. Results: We identified 32 potentially relevant articles, but only 4 RCTs, which had enrolled a total of 168 patients, were included. Our meta-analysis demonstrated that MMF treatment did not have statistically significant effects in reducing proteinuria or protecting renal function in patients with IgAN. Conclusion: The currently available evidence does not support the routine use of MMF in patients with IgAN. Larger international collaborations should be put in place to further address this issue.
- 31 October 2008
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 29 (5) , 362-367
Mycophenolate Mofetil Treatment for IgA Nephropathy: A Meta-Analysis
Background: Worldwide, IgA nephropathy (IgAN) is the most common type of glomerulonephritis. Mycophenolate mofetil (MMF) is relatively selective for lymphocytes and inhibits antibody production by B cells more than other immunosuppressants. Several randomized controlled trials (RCTs) have analyzed the role of MMF in patients with IgAN. We conducted this meta-analysis of all available RCTs to ascertain the benefits and risks of MMF treatment in comparison with placebos or steroids in patients with IgAN. Methods: The studies were identified by extended computer- based searches of the PubMed database (April, 2008) and the Cochrane Library, without language restriction. References in Medline-cited studies were reviewed to identify additional reports not indexed by Medline. RCTs comparing treatment of IgAN with mycophenolate against placebo or steroids were included in the analysis. Results: We identified 32 potentially relevant articles, but only 4 RCTs, which had enrolled a total of 168 patients, were included. Our meta-analysis demonstrated that MMF treatment did not have statistically significant effects in reducing proteinuria or protecting renal function in patients with IgAN. Conclusion: The currently available evidence does not support the routine use of MMF in patients with IgAN. Larger international collaborations should be put in place to further address this issue.